论文部分内容阅读
目的评价腹腔化疗对胃癌术后腹膜转移患者腹腔冲洗细胞学转阴率及对生存期的影响。方法2003至2005年共收治16例胃癌腹膜种植及8例腹腔冲洗细胞学(P0Cy+)患者,于术中留置腹腔化疗管,定期灌注顺铂(CDDP)、丝裂霉素(MMC),平均灌注次数5.6次,CDDP总量为288mg。结果化疗后腹腔冲洗细胞学转阴率为71.4%,P0Cy+组转阴率更高;治疗后转阴组的中位生存时间(777d)和无效组(254d)相比明显延长,化疗副作用包括腹胀、腹泻、恶心、呕吐、肝肾功能损害、骨髓抑制。结论本疗法对于胃癌腹膜种植高危人群、P0Cy+患者疗效显著。
Objective To evaluate the influence of intraperitoneal chemotherapy on cytological rejection rate and survival rate of patients with peritoneal metastasis of gastric cancer after peritoneal chemotherapy. Methods From 2003 to 2005, 16 patients with peritoneum of gastric cancer and 8 patients with peritoneal lavage cytology (P0Cy +) were enrolled. Intraperitoneal chemotherapy tubes, cyclophosphamide (MMC) and cisplatin (MMC) The number of 5.6 times, the total amount of CDDP 288mg. Results After chemotherapy, the cytological rejection rate was 71.4% and the negative conversion rate was higher in the P0Cy + group. The median survival time (777d) in the negative control group was significantly longer than that in the ineffective group (254d) after chemotherapy. Chemotherapy side effects included abdominal distension , Diarrhea, nausea, vomiting, impaired liver and kidney function, myelosuppression. Conclusion The therapy has a significant effect on patients with high risk of peritoneal implantation of gastric cancer and P0Cy +.